Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

58 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Vascular risk factors are associated with a decline in resting-state functional connectivity in cognitively unimpaired individuals at risk for Alzheimer's disease: Vascular risk factors and functional connectivity changes.
Köbe T, Binette AP, Vogel JW, Meyer PF, Breitner JCS, Poirier J, Villeneuve S; Presymptomatic Evaluation of Novel or Experimental Treatments for Alzheimer Disease (PREVENT-AD) Research Group. Köbe T, et al. Among authors: meyer pf. Neuroimage. 2021 May 1;231:117832. doi: 10.1016/j.neuroimage.2021.117832. Epub 2021 Feb 4. Neuroimage. 2021. PMID: 33549747 Free article.
No apparent effect of naproxen on CSF markers of innate immune activation.
Meyer PF, Labonté A, Rosa-Neto P, Poirier J, Breitner JCS; PREVENT‐AD Research Group. Meyer PF, et al. Ann Clin Transl Neurol. 2019 Jun 6;6(6):1127-1133. doi: 10.1002/acn3.788. eCollection 2019 Jun. Ann Clin Transl Neurol. 2019. PMID: 31211178 Free PMC article. Clinical Trial.
Association of Vascular Risk Factors With β-Amyloid Peptide and Tau Burdens in Cognitively Unimpaired Individuals and Its Interaction With Vascular Medication Use.
Köbe T, Gonneaud J, Pichet Binette A, Meyer PF, McSweeney M, Rosa-Neto P, Breitner JCS, Poirier J, Villeneuve S; Presymptomatic Evaluation of Experimental or Novel Treatments for Alzheimer Disease (PREVENT-AD) Research Group. Köbe T, et al. Among authors: meyer pf. JAMA Netw Open. 2020 Feb 5;3(2):e1920780. doi: 10.1001/jamanetworkopen.2019.20780. JAMA Netw Open. 2020. PMID: 32031648 Free article.
Amyloid and Tau Pathology Associations With Personality Traits, Neuropsychiatric Symptoms, and Cognitive Lifestyle in the Preclinical Phases of Sporadic and Autosomal Dominant Alzheimer's Disease.
Pichet Binette A, Vachon-Presseau É, Morris J, Bateman R, Benzinger T, Collins DL, Poirier J, Breitner JCS, Villeneuve S; Dominantly Inherited Alzheimer Network (DIAN); PREVENT-AD Research Group. Pichet Binette A, et al. Biol Psychiatry. 2021 Apr 15;89(8):776-785. doi: 10.1016/j.biopsych.2020.01.023. Epub 2020 Feb 6. Biol Psychiatry. 2021. PMID: 32228870 Free PMC article.
58 results